The North America Blood Screening Market is projected for robust expansion between 2020 and 2035 owing to technological advancements, increasing prevalence of infectious diseases, and government initiatives for blood safety. The market size was valued at USD 2,560 Million in 2025 and is anticipated to reach approximately USD 5,870 Million by 2035, growing at a CAGR of 7.6% during the forecast period.
The economic impact of tariffs on "North America Blood Screening Market".
North America Blood Screening Market Growth Drivers
Rising Prevalence of Transfusion-Transmissible Infections: The increase in cases of transfusion-transmissible infections such as HIV, Hepatitis B, and Hepatitis C has elevated the demand for blood screening across North America. Strict regulatory frameworks and standards implemented by organizations like the FDA have compelled hospitals and blood banks to prioritize advanced screening. For example, Grifols, a leading healthcare company, has expanded its nucleic acid testing (NAT) portfolio in North America, enhancing early detection of infections and ensuring blood safety.
Technological Innovations in Screening Methods: Advancements in blood screening technologies, such as automated platforms, next-generation sequencing, and multiplex assays, have accelerated the accuracy, speed, and scalability of tests. Companies like Abbott Laboratories have launched advanced serological and molecular testing systems, offering real-time pathogen detection and supporting hospitals in meeting higher throughput demands during public health crises such as the COVID-19 pandemic.
North America Blood Screening Market Trends
Shift Toward Automation and Digitalization: The industry witnesses a notable shift towards automated and digital blood screening processes. Automated systems reduce manual errors, increase process efficiencies, and result in faster turnaround times for diagnostic labs and hospitals. For instance, Roche Diagnostics has implemented fully automated analyzers with advanced data analytics to manage large-scale screening activities and streamline operations across North American blood centers.
Rising Adoption of NAT and Pathogen Reduction Technologies: There is a steady adoption of NAT and pathogen reduction technologies owing to their superior sensitivity and specificity. These technologies are becoming standard in blood banks and transfusion centers for detecting a wider spectrum of blood-borne pathogens. Bio-Rad Laboratories has expanded its NAT product range, enabling earlier and more comprehensive detection of infectious agents and supporting safer blood transfusion protocols.
North America Blood Screening Market Opportunities
Expansion in Personalized and Precision Medicine: Increased focus on personalized medicine and development of patient-matched blood products offers significant opportunities for specialized blood screening assays. Integrated DNA Technologies recently collaborated with major U.S. hospitals to develop precision screening panels tailored to individual patient risk profiles.
Emerging Point-of-Care Testing (POCT): Demand for rapid and portable POCT screening solutions is rising, especially in remote areas and emergency settings. Companies like QuidelOrtho have introduced cost-effective rapid test kits, creating growth opportunities across untapped market segments.
North America Blood Screening Market Revenue (USD Million), 2020-2035
The market revenue chart illustrates a steady upward trajectory for the North America Blood Screening Market between 2020 and 2035. Starting at USD 1,620 Million in 2020, the market experiences consistent year-on-year growth, reaching approximately USD 2,560 Million in 2025. This upward climb continues driven by factors like technological innovations and increased screening demand, with market revenue surging to nearly USD 5,870 Million by 2035. The robust growth is further bolstered by regulatory support and strategic industry partnerships. The chart highlights considerable expansion opportunities, particularly in the latter part of the forecast period.
North America Blood Screening Market by Regional Share (%), 2025
In 2025, the United States holds the dominant share in the North America Blood Screening Market, accounting for 73% of revenues, attributed to its advanced healthcare infrastructure and expansive screening programs. Canada follows with a 20% share, benefitting from national screening initiatives. Mexico represents 5%, showing steady growth due to rising healthcare investments. 'Rest of North America' regions jointly capture 2%. The chart underscores the U.S.’s market leadership while indicating emerging opportunities in Canada and Mexico as these countries continue prioritizing blood safety.
Recent Developments in North America Blood Screening Market (Past 6 Months)
In March 2024, Abbott Laboratories announced FDA clearance for its Alinity m Resp-4-Plex molecular assay for blood screening. The multiplex panel is designed to simultaneously detect and distinguish between multiple respiratory viruses in donated blood, enhancing Abbott’s diagnostics portfolio and reinforcing blood screening safety across major U.S. hospitals.
In February 2024, Grifols unveiled its partnership with the Canadian Blood Services to pilot next-generation nucleic acid testing platforms for fast-tracking the detection of emerging pathogens. This collaboration aims to enhance the reliability and turnaround speed of blood screening protocols, supporting the smooth supply of safe blood products across Canada.
In January 2024, Roche Diagnostics launched its upgraded Cobas 8800 System in the North American market, offering high-throughput, fully automated blood screening for major infectious agents. The new system integrates AI-powered analytics to optimize workflow in blood banks, reduce manual intervention, and ensure consistent testing accuracy.
Press Releases